Aspacytarabine (BST-236), a possibly less toxic form of chemotherapy being developed by Biosight for people with acute myeloid leukemia (AML), has been designated an orphan medicinal product by the European Medicines Agency (EMA). This follows the orphan drug designation granted to aspacytarabine by the U.S. Food and Drug Administration for the treatment of AML in June 2019. Both designations are expected to support and expedite the clinical development and regulatory review of aspacytarabine, by providing benefits that include…

You must be logged in to read/download the full post.